METROPOLIS.NS Stock Analysis
ME
Avoid
Based on Eyestock quantitative analysis, METROPOLIS.NS`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly overvalued
Market cap $B
0.573
Dividend yield
0.74 %
Shares outstanding
51.227 B
Metropolis Healthcare Ltd. owns and operates medical laboratories. The company is headquartered in Mumbai, Maharashtra and currently employs 4,289 full-time employees. The company went IPO on 2019-04-15. The firm operates through the pathology services segment. The firm offers a range of clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation, and monitoring of the disease. The firm also offers analytical and support services to clinical research organizations for their clinical research projects. Its services include pathology testing services, corporate wellness, lab in hospitals and clinical research services. The firm offers a range of tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. The company owns a chain of diagnostic centers across India, South Asia, Africa, and the Middle East. The firm has spread its footprint across 20 Indian states and over 220 cities.